Lisata Therapeutics Begins Second Cohort Treatment In Bile Duct Cancer Trial

September 18, 2024 02:26 AM AEST | By Team Kalkine Media

Google News:

Lisata Therapeutics Begins Second Cohort Treatment In Bile Duct Cancer Trial — Image source: Shutterstock

Recent News

Innovating for Impact: Covia’s 2024 Corporate Responsibility Highlight...

3i Announces Prime Day 2025 Sale with Major Savings on Flagship and Al...

Global Times: Beyond Tchaikovsky and Tolstoy: Meet Lomonosov

Kismile Launches Roasti™ 5-in-1 Portable Glass Air Fryer: A Stylish, S...

Lisata Therapeutics Inc (NASDAQ:LSTA). has initiated treatment in the second-line cholangiocarcinoma (CCA) cohort of its BOLSTER trial. Cholangiocarcinoma, often referred to as bile duct cancer, is a rare and aggressive cancer with a five-year survival rate below 5%. This low survival rate underscores the significant need for advancements in treatment options.

The BOLSTER trial is a Phase 2a, multi-center trial that explores the efficacy of Lisata's investigational drug, certepetide, in combination with standard-of-care treatments for patients with first- or second-line CCA. This drug is designed to enhance the delivery and effectiveness of cancer therapies by improving penetration within tumors and altering the tumor microenvironment, potentially offering new hope for those affected by this condition.

Certepetide has demonstrated promising safety and efficacy profiles in earlier clinical trials. Additionally, it has been granted important designations such as Fast Track and Orphan Drug status for its potential role in treating various cancers. These designations aim to expedite the drug's development process and bring effective treatments to patients more quickly.

According to Lisata’s Chief Medical Officer, Dr. Kristen Buck, the decision to initiate treatment in the second-line cohort stems from recommendations made by investigators involved in the first-line cholangiocarcinoma cohort. Dr. Buck emphasized that the expansion of the trial seeks to improve outcomes for patients who have not responded to first-line treatments alone, reflecting the company's commitment to exploring new avenues for treatment.

Lisata Therapeutics has been gaining attention for its innovative approaches in cancer treatment, and certepetide is seen as a potential breakthrough for patients with hard-to-treat cancers like CCA. As the trial progresses, the company aims to gather more data to determine the drug’s broader impact and potential in improving patient survival rates.

This development marks another step forward for the healthcare sector in advancing cancer treatments, particularly for rare and challenging forms like cholangiocarcinoma

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.